65,437 trials
HIV Infections
Primary: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 — 77.3; 42.9 Percentage of Participants
Lung Cancer, Small Cell
Primary: Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the…
Neuralgia, Postherpetic
Primary: Summary of Adverse Events — 124; 14; 5; 17 subjects
Anemia
Primary: Serum Ferritin — 26.7 ng/mL
Gastrointestinal Stromal Tumor
Primary: Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase — 27.3; 6.4 weeks — p=<0.001
HIV Infections
Primary: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 — 77.7; 41.0 Percentage of Participants
Astigmatism
Primary: Lens Orientation During Head Tilt. — 12.2; 39.7; 27.6; 39.3 Degree of rotation — p=<0.0001
Diphtheria · Tetanus · Pertussis
Primary: Percentage of Participants Reporting Solicited Local or Systemic Reactions Post-Dose 5 of DAPTACEL® Vaccination — 75; 70; 36; 24 Percentage of Participants
Neoplasm, Gastric
Primary: Objective Best Tumor Response — 1; 15; 22; 24 participants
Iron Deficiency Anemia
Primary: Hemoglobin — 1.49; 0.89; 1.02 ng/mL
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 12 — -0.41; -0.71; -0.69; -0.76 Percent — p=<0.001
Diabetes
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy — 9.41; 9.53; 9.61; 6.93 percent
Breast Cancer · Ovarian Cancer · Endometrial Cancer
Primary: Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A. — 0; 0; 1; 2 Participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — 8.25; 8.35; 8.19; 7.59 percent
Diabetes
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — 8.36; 8.48; 8.44; 7.83 percent